New inhaled drug aims to stop lung infections in vulnerable blood cancer patients

NCT ID NCT06665100

Recruiting now Disease control Sponsor: Pulmotect, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can reduce the severity of lung complications within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PUL-042 inhalation solution
What this could lead to: If successful, this could provide a new treatment to prevent severe lung infections in vulnerable patients with blood cancers or after stem cell transplants.
What could go wrong: This is an early Phase 2 trial with only 100 participants, so results may not be conclusive. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Hodgkins lymphoma leukemia lymphoma myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm myeloproliferative neoplasm non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
John Theurer Cancer Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21205, United States
Lineberger Cancer
RECRUITING

Chapel Hill, North Carolina, 27514, United States
Memorial Sloan Kettering Cancer Center
ACTIVE_NOT_RECRUITING

New York, New York, 10065, United States
Northside Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
OU Health Physicians - Infectious Disease Clinic
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Texas MD Anderson MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.